Curis, Inc. (CRIS)

NASDAQ: CRIS · IEX Real-Time Price · USD
0.800
+0.007 (0.88%)
At close: Dec 2, 2022 4:00 PM
0.820
+0.020 (2.50%)
Pre-market: Dec 5, 2022 4:00 AM EST
0.88%
Market Cap 76.44M
Revenue (ttm) 10.41M
Net Income (ttm) -58.96M
Shares Out 93.79M
EPS (ttm) -0.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 448,171
Open 0.79
Previous Close 0.793
Day's Range 0.765 - 0.82
52-Week Range 0.68 - 5.27
Beta 2.67
Analysts Buy
Price Target 9.95 (+1,143.8%)
Earnings Date Nov 9, 2022

About CRIS

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, a... [Read more]

Industry Biotechnology
IPO Date Aug 1, 2000
CEO James Dentzer
Employees 60
Stock Exchange NASDAQ
Ticker Symbol CRIS
Full Company Profile

Financial Performance

In 2021, Curis's revenue was $10.65 million, a decrease of -1.72% compared to the previous year's $10.84 million. Losses were -$45.44 million, 51.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for CRIS stock is "Buy." The 12-month stock price forecast is 9.95, which is an increase of 1,143.75% from the latest price.

Price Target
$9.95
(1,143.75% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Curis (CRIS) Reports Q3 Loss, Misses Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of 17.65% and 6.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Curis Provides Third Quarter 2022 Business Update

Data from additional patients in the TakeAim Leukemia trial of emavusertib to be presented during ASH 2022 Curis focuses its resources to drive the development of emavusertib Cash runway extended into 2...

3 weeks ago - PRNewsWire

Curis Announces Three Presentations at SITC 2022

LEXINGTON, Mass. , Nov. 7, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...

3 weeks ago - PRNewsWire

Curis to Release Third Quarter 2022 Financial Results and Hold Conference Call on November 9, 2022

LEXINGTON, Mass. , Nov. 2, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...

1 month ago - PRNewsWire

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass. , Oct. 7, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...

1 month ago - PRNewsWire

Curis Announces Date for the 1st Symposium on IRAK4 in Cancer

Symposium hosted by Guillermo Garcia-Manero, M.D.; Hagop Kantarjian, M.D.

2 months ago - PRNewsWire

Curis Announces Date for the 2nd Annual VISTA Symposium

Industry experts in immuno-oncology will gather to discuss VISTA on September 23, 2022 Symposium hosted by Randolph Noelle, Ph.D. LEXINGTON, Mass.

2 months ago - PRNewsWire

Curis to Present at Upcoming Healthcare Conferences in September

LEXINGTON, Mass. , Sept. 7, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced th...

2 months ago - PRNewsWire

Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study

The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplastic ...

3 months ago - Zacks Investment Research

FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study

Curis working with clinical sites to resume enrollment Preliminary clinical data update expected in 2023 LEXINGTON, Mass. , Aug. 30, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology comp...

3 months ago - PRNewsWire

Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain

The FDA lifts partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares surge.

3 months ago - Zacks Investment Research

Why Is Curis (CRIS) Stock Up 20% Today?

Source: Gorodenkoff / Shutterstock.com Today is a big day for biotech firm Curis (NASDAQ: CRIS ) and CRIS stock. The U.S. Food and Drug Administration (FDA) just completed its review of the company's Ta...

3 months ago - InvestorPlace

FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib

Curis working with clinical sites to resume enrollment  Preliminary clinical data update expected in 2023 LEXINGTON, Mass. , Aug. 18, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology com...

3 months ago - PRNewsWire

Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of 0% and 1.40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Curis Reports Second Quarter 2022 Financial Results and Business Update

Presented encouraging clinical data for the combination of emavusertib plus ibrutinib showing tumor reduction in 8 of 9 evaluable patients and the potential for overcoming ibrutinib resistance at the 20...

4 months ago - PRNewsWire

Curis Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass. , July 29, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced th...

4 months ago - PRNewsWire

Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022

LEXINGTON, Mass. , July 28, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced th...

4 months ago - PRNewsWire

6 Penny Stocks With 1,000% Upside Potential

Each of these penny stocks with 1,000% upside potential could rise 10X in the future for investors with a high risk tolerance. The post 6 Penny Stocks With 1,000% Upside Potential appeared first on Inve...

Other symbols: AGTCALZNAMPEBRDSDRRX
4 months ago - InvestorPlace

Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology ...

Curis scientists discover novel IRAK4 nuclear localization and describe potential use as a biomarker IRAK4 along with NF-kB p50/p65 localization to the nucleus is associated with improved response to em...

5 months ago - PRNewsWire

Curis Shares Gain On Encouraging Data Presentation From Blood Cancer Trials At ASCO Meeting

Curis Inc (NASDAQ: CRIS) presented clinical data from the TakeAim Lymphoma and TakeAim Leukemia studies at the 2022 American Society of Clinical Oncology Annual Meeting. The TakeAim Lymphoma Phase 1/2 s...

5 months ago - Benzinga

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

TakeAim Lymphoma data for the combination of emavusertib plus ibrutinib show tumor reduction in 8 of 9 evaluable patients, including 2 complete responses and 2 partial responses Potential for overcoming...

6 months ago - PRNewsWire

Curis to Present at 2022 Jefferies Global Healthcare Conference

LEXINGTON, Mass. , June 2, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced tha...

6 months ago - PRNewsWire

Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA)

Initial TakeAim Lymphoma combination data shows anti-cancer activity, including 1 complete response and 2 partial responses, in heavily pretreated patients including those with prior ibrutinib use LEXIN...

6 months ago - PRNewsWire

Curis (CRIS) Reports Q1 Loss, Misses Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of -5.88% and 6.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Curis Reports First Quarter 2022 Financial Results and Business Update

Strong balance sheet with $120.7 million in cash and investments at March 31, 2022; no change to cash guidance: cash runway into 2024 Potential opportunity for emavusertib in pancreatic cancer highlight...

6 months ago - PRNewsWire